Page last updated: 2024-11-13

verdinexor

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

verdinexor: a selective inhibitor of nuclear export [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71492799
CHEMBL ID3545187
SCHEMBL ID14678337
MeSH IDM000600782

Synonyms (40)

Synonym
S7707
unii-85q03215iw
verdinexor
kpt-335
2-propenoic acid, 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1h-1,2,4-triazol-1-yl)-, 2-(2-pyridinyl)hydrazide, (2z)-
verdinexor [usan:inn]
85q03215iw ,
(2z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1h-1,2,4-triazol-1-yl)-n'-(pyridin-2-yl)prop-2-enehydrazide
1392136-43-4
verdinexor [inn]
verdinexor [usan]
1656285-28-7
(z)-3-(3-(3,5-bis-(trifluoromethyl)phenyl)-1h-1,2,4-triazol-1-yl)-n'-(pyridin-2-yl)acrylohydrazide
(z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1h-1,2,4-triazol-1-yl)-n'-(pyridin-2-yl)acrylohydrazide
SCHEMBL14678337
verdinexor (kpt-335)
AC-32682
CHEMBL3545187
J-690155
2-[(5-chloro-2-{[4-(1-piperazinyl)phenyl]amino}-4-pyrimidinyl)amino]-n-methylbenzamide
EX-A871
kpt335;verdinexor
AKOS030526476
kpt 335
DB12207
(z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyridin-2-ylprop-2-enehydrazide
BS-15021
kpt335
BCP11733
verdinexor (usan/inn)
D11223
CCG-269150
Q27269660
NCGC00386421-08
DTXSID301022535
laverdia-ca1
verdinexorum
85qo3215iw
HY-15970
CS-3471

Research Excerpts

Overview

Verdinexor is a novel orally bioavailable selective inhibitor of nuclear export. It inhibits the function of the nuclear export protein Exportin 1 (XPO1/CRM1)

ExcerptReferenceRelevance
"Verdinexor (KPT-335) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) compound that inhibits the function of the nuclear export protein Exportin 1 (XPO1/CRM1). "( The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines.
Breitbach, JT; Davies, AE; Fenger, JM; Louke, DS; Tobin, SJ; Watts, MR, 2021
)
2.32

Bioavailability

Verdinexor (KPT-335) inhibits the function of the nuclear export protein Exportin 1 (XPO1/CRM1) It exhibited anti-tumor activity against non-Hodgkin lymphoma in a prior phase I study.

ExcerptReferenceRelevance
"This study provides evidence that the novel orally bioavailable XPO1 inhibitor KPT-335 is safe and exhibits activity in a relevant, spontaneous large animal model of cancer."( Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
Barnard, S; Bear, MD; Bernabe, LF; Borgatti, A; Henson, M; Ito, D; Jensen, K; Kauffman, M; Kisseberth, WC; London, CA; McCauley, D; Modiano, JF; Pennell, ML; Saint-Martin, JR; Shacham, S; Wilson, H, 2014
)
0.4
" The present study sought to characterize the biologic activity of an orally bioavailable selective inhibitor of nuclear export (SINE), KPT-335, against canine melanoma cell lines as a prelude to future clinical trials in dogs with melanoma."( Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
Bear, MD; Breit, MN; Kashyap, T; Kauffman, MG; Kisseberth, WC; Landesman, Y; London, CA; McCauley, D; Shacham, S, 2014
)
0.4
" Selective inhibitors of nuclear export (SINE) are small orally bioavailable molecules that serve as drug-like inhibitors of XPO1, with potent anti-cancer properties."( A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus.
Acosta, SA; Borlongan, CV; Carlson, R; De La Peña, I; Kaneko, Y; Landesman, Y; Shacham, S; Tajiri, N; Tamir, S, 2016
)
0.43
" In this review, we examine the use of Verdinexor (KPT-335, a novel orally bioavailable drug that functions as a selective inhibitor of nuclear export, SINE), as an antiviral with multifaceted therapeutic potential."( Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.
Pickens, JA; Tripp, RA, 2018
)
2.19
" KPT-335 (verdinexor) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) that exhibited anti-tumor activity against non-Hodgkin lymphoma in a prior phase I study."( Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.
Borgatti, A; Gardner, HL; Klein, MK; Lachowicz, J; London, CA; Manley, C; Sadowski, AR; Sahora, A; Turner, A; Vail, DM; Waite, A; Wilson, H, 2018
)
1.11
"Verdinexor (KPT-335) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) compound that inhibits the function of the nuclear export protein Exportin 1 (XPO1/CRM1)."( The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines.
Breitbach, JT; Davies, AE; Fenger, JM; Louke, DS; Tobin, SJ; Watts, MR, 2021
)
2.32

Dosage Studied

ExcerptRelevanceReference
" Binding to XPO1 was quantitated from SINE compound treated adherent and suspension cells in vitro, dosed ex vivo human peripheral blood mononuclear cells (PBMCs), and PBMCs from mice dosed orally with drug in vivo."( A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Baloglu, E; Crochiere, ML; Del Alamo, D; Donovan, S; Kauffman, M; Klebanov, B; Landesman, Y; Lee, M; Shacham, S, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency2.33620.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency2.33620.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1524157Selectivity ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/WSN/33)2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
AID1524156Cytotoxicity against MDCK cells assessed as cell death after 72 hrs by MTT assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
AID1524155Antiviral activity against Influenza A virus (A/WSN/33) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 72 hrs by crystal violet-staining based assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's11 (64.71)24.3611
2020's6 (35.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.90 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index53.92 (26.88)
Search Engine Supply Index2.05 (0.95)

This Compound (38.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (11.76%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (82.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]